tiprankstipranks
Rainbow Childrens Medicare Limited (IN:RAINBOW)
:RAINBOW
India Market
Want to see IN:RAINBOW full AI Analyst Report?

Rainbow Childrens Medicare Limited (RAINBOW) AI Stock Analysis

3 Followers

Top Page

IN:RAINBOW

Rainbow Childrens Medicare Limited

(RAINBOW)

Select Model
Select Model
Select Model
Outperform 72 (OpenAI - 5.2)
Rating:72Outperform
Price Target:
₹1,505.00
▲(11.58% Upside)
Action:Upgraded
Date:05/25/26
The score is driven primarily by solid financial performance (steady growth, strong margins, and improving leverage) and supportive technical momentum (price above key moving averages with positive MACD). The main constraint is valuation, with a high P/E and minimal dividend yield, plus the risk signaled by uneven free-cash-flow conversion.
Positive Factors
Specialized Clinical Focus
Rainbow’s clear specialization in pediatric and women’s health (including maternity, neonatal and NICU/PICU care) creates durable demand and clinical complexity. That focus builds referral networks, repeat patient flows and differentiated service capability that support stable volumes and higher-acuity revenues over time.
Negative Factors
Volatile Free Cash Flow
Wide swings in free cash flow reflect uneven timing of reinvestment and capex, undermining predictability of cash available for debt service, dividends, or opportunistic investment. Persistent volatility can constrain strategic choices and increase reliance on external funding during down years.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized Clinical Focus
Rainbow’s clear specialization in pediatric and women’s health (including maternity, neonatal and NICU/PICU care) creates durable demand and clinical complexity. That focus builds referral networks, repeat patient flows and differentiated service capability that support stable volumes and higher-acuity revenues over time.
Read all positive factors

Rainbow Childrens Medicare Limited (RAINBOW) vs. iShares MSCI India ETF (INDA)

Rainbow Childrens Medicare Limited Business Overview & Revenue Model

Company Description
Rainbow Children's Medicare Limited is a leading Indian healthcare provider managing a network of multi-specialty hospitals dedicated to pediatric, obstetrics, and gynecology services. Its comprehensive child health offerings include general pedia...
How the Company Makes Money
RAINBOW primarily earns revenue by delivering hospital and clinical care services to patients. Key revenue streams include (1) inpatient and outpatient clinical services in pediatrics and in obstetrics & gynecology (e.g., consultations, procedures...

Rainbow Childrens Medicare Limited Financial Statement Overview

Summary
Strong and steady revenue growth with consistently healthy net margins supports a solid fundamental profile, and leverage has improved meaningfully over time. The main offsets are volatile free-cash-flow conversion (notably the sharp drop in 2026) and some gross margin compression in 2026.
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue15.66B17.03B15.16B12.97B11.74B9.74B
Gross Profit8.41B6.73B10.82B9.31B8.44B6.44B
EBITDA4.99B5.86B4.37B3.90B3.65B2.73B
Net Income2.54B2.78B2.43B2.17B2.11B1.38B
Balance Sheet
Total Assets25.87B27.75B23.77B21.70B17.76B14.24B
Cash, Cash Equivalents and Short-Term Investments4.42B4.38B6.94B5.02B3.81B2.03B
Total Debt8.16B8.91B7.64B7.65B5.70B5.79B
Total Liabilities10.54B11.11B9.02B9.05B7.06B6.89B
Stockholders Equity15.18B16.48B14.68B12.59B10.60B6.03B
Cash Flow
Free Cash Flow-946.85M1.37B2.50B-321.75M1.86B1.62B
Operating Cash Flow2.08B3.54B3.96B3.21B3.27B2.24B
Investing Cash Flow-1.25B-2.70B-2.68B-2.26B-4.65B-1.75B
Financing Cash Flow-762.19M-697.53M-1.18B-1.02B1.43B-440.62M

Rainbow Childrens Medicare Limited Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1348.80
Price Trends
50DMA
1292.93
Positive
100DMA
1236.56
Positive
200DMA
1308.51
Positive
Market Momentum
MACD
15.18
Positive
RSI
60.36
Neutral
STOCH
50.28
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:RAINBOW, the sentiment is Positive. The current price of 1348.8 is below the 20-day moving average (MA) of 1351.34, above the 50-day MA of 1292.93, and above the 200-day MA of 1308.51, indicating a bullish trend. The MACD of 15.18 indicates Positive momentum. The RSI at 60.36 is Neutral, neither overbought nor oversold. The STOCH value of 50.28 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:RAINBOW.

Rainbow Childrens Medicare Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
₹138.49B49.780.22%12.35%14.32%
67
Neutral
₹1.22T62.920.27%15.76%34.29%
67
Neutral
₹747.71B71.800.11%17.28%34.55%
66
Neutral
₹332.09B59.630.04%19.44%15.55%
64
Neutral
₹386.91B47.760.24%41.43%2.10%
61
Neutral
₹985.12B68.240.14%19.14%34.04%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:RAINBOW
Rainbow Childrens Medicare Limited
1,363.65
-83.77
-5.79%
IN:APOLLOHOSP
Apollo Hospitals Enterprise Limited
8,496.45
1,406.51
19.84%
IN:FORTIS
Fortis Healthcare Ltd.
990.40
226.30
29.62%
IN:MAXHEALTH
Max Healthcare Institute Ltd
1,012.20
-233.36
-18.74%
IN:MEDANTA
Global Health Limited
1,235.15
18.34
1.51%
IN:NH
Narayana Hrudayalaya Ltd.
1,893.25
-40.65
-2.10%

Rainbow Childrens Medicare Limited Corporate Events

Rainbow Children’s Medicare Files SEBI Regulation 74(5) Compliance Certificate
Apr 7, 2026
Rainbow Children’s Medicare Limited has submitted to NSE and BSE a compliance certificate obtained from its registrar and share transfer agent, KFIN Technologies Limited, under Regulation 74(5) of the SEBI (Depositories and Participants) Reg...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 25, 2026